Recently Featured

Exclusive: Mystery Man Granted Compassionate Use of Experimental GLP-1

July 2, 2026
In a remarkable development within the pharmaceutical landscape, a single individual has been granted compassionate-use access to Eli Lilly’s experimental GLP-1 obesity drug. This unprecedented decision raises questions about the criteria and processes governing access to unapproved therapies, particularly in the context of increasing demand for innovative obesity treatments. The case, reported by Lizzy Lawrence,…

Kardigan Capitalizes on Deal Leftovers for $400M IPO

July 2, 2026
Kardigan has successfully launched a $400 million initial public offering (IPO), leveraging late-stage assets and a seasoned team previously involved with MyoKardia. This strategic positioning has attracted significant investor interest, as highlighted by CEO Tassos Gianakakos. The recent high-profile IPO of SpaceX has also created a favorable market environment, enhancing investor confidence in biotech ventures.…

Reliable Clinical Trial Data Begins in Phase 1: Ensuring Safety and Sponsor Confidence

July 2, 2026
Reliable clinical trial data starts in Phase 1, a critical phase that sets the foundation for the entire clinical development process. Early quality signals are essential in identifying potential safety issues and ensuring that data integrity is maintained from the outset. This proactive approach not only protects patient safety but also enhances the credibility of…

BIO 2026: Cell and gene therapy firms outline their use of AI in manufacturing

July 2, 2026
At BIO 2026, leading cell and gene therapy companies Kriya, Opus, and Epicrispr have revealed their innovative applications of artificial intelligence in manufacturing processes. This strategic integration of AI technologies aims to enhance operational efficiency, reduce production times, and improve product quality, addressing the increasing demand for advanced therapies. The context of this development highlights…

Ongoing Cases